Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RSV vaccine 1

Phase 2Vaccine

RSV vaccine 1 is one of 41 biologic programs targeting Influenza. It is currently in Phase 2.

2

Indications

8

Total Trials

2

Active Trials

40

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

Respiratory Syncytial VirusCompleted

InfluenzaPhase 1

Active, not recruiting

Respiratory Syncytial VirusPhase 2

Completed

Competition

Competitive Landscape

93 competitors in Influenza

#DrugCompanyPhaseTrials

Influenza Vaccine

FLU Vaccine

Inactivated Influenza Vaccine

Live Attenuated Zoster Vaccine

CChangchun BCHT Biotechnology Co.

Relenza

GGlaxo Dba Glaxosmithkline

Seasonal Influenza Vaccine

VAXIGRIP

Dexametasone

UUniversity of Malaya

Baloxavir

IInsight Therapeutics, LLC

GP681

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus4 trials

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT04491877·259 enrolled

Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Completed· Sanofi logo

Sanofi·Phase 2·NCT06251024·4,541 enrolled

Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 1·NCT07071558·240 enrolled

Show 1 more trial

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Completed· Sanofi logo

Sanofi·Phase 1·NCT06237296·558 enrolled

Respiratory Syncytial Virus (RSV)2 trials

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Completed· GSK logo

GSK·Phase 2·NCT02956837·406 enrolled

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Withdrawn· GSK logo

GSK·Phase 2·NCT03191383

Influenza1 trial

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Active, not recruiting· Sanofi logo

Sanofi·Phase 1·NCT06604767·390 enrolled

Respiratory Syncytial Virus Immunization1 trial

A Phase I/IIa, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV Vaccine Candidate in Adult Participants 18 to 50 Years of Age in Phase I, and 60 Years and Older in Phase IIa

Completed· Sanofi logo

Sanofi·Preclinical·NCT05639894·865 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for RSV vaccine 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RSV vaccine 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RSV vaccine 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Related News